Novel Benzophenones as Non-nucleoside Reverse Transcriptase Inhibitors of HIV-1

Journal of Medicinal Chemistry

Volumn 47, Issue 5, 2004, Pages 1175-1182

  Chan, Joseph H ^a,b   Freeman, George A ^a   Tidwell, Jeffrey H ^a   Romines, Karen R ^a   Schaller, Lee T ^a   Cowan, Jill R ^a   Gonzales, Steve S ^a   Lowell, Gina S ^a   Andrews III, C W ^a   Reynolds, David J ^a   St Clair, Marty ^a   Hazen, Richard J ^a   Ferris, Rob G ^a   Creech, Katrina L ^a   Roberts, Grace B ^a   Short, Steven A ^a   Weaver, Kurt ^a   Koszalka, George W ^a   Boone, Lawrence R ^a  

^a GLAXOSMITHKLINE   (United States)

^b Development and Medical Affairs Division   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOPHENONE DERIVATIVE; DELAVIRDINE; EFAVIRENZ; GW 3011; GW 4511; GW 4751; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DOG; DRUG BLOOD LEVEL; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MONKEY; NONHUMAN; RAT; VIRUS INHIBITION; VIRUS MUTANT;

ANTI-HIV AGENTS; BENZOPHENONES; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; INHIBITORY CONCENTRATION 50; MUTATION; PROTEIN BINDING; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 10744228247     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030255y     Document Type: Article

References (19)

1. Palella, F. J.; Delaney, K. M.; Moorman, A. C.; Loveless, M. O.; Fuhrer, J.; Satten, G. A.; Aschman, D. J.; Holmberg, S. D.for The HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 1998, 338, 853-860.
2. Koup, R. A.; Merluzzi, V. J.; Hargrave, J. L.; Adams, J.; Grozinger, K.; Eckner, R. J.; Sullivan, J. L. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. J. Infect. Dis. 1991, 163, 966-970.
3. Freimuth, W. W. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Adv. Exp. Med. Biol. 1996, 394, 279-289.
4. Young, S. D.; Britcher, S. F.; Tran, L. O.; Payne, L. S.; Lumma, W. C.; Lyle, T. A.; Huff, J. R.; Anderson, P. S.; Olsen, D. B.; Carroll, S. S.; Pettibone, D. J.; O'Brien, J. A.; Ball, R. G.; Balani, S. K.; Lin, J. H.; Chen, I.-W.; Schleif, W. A.; Sardana, V. V.; Long, W. J.; Byrnes, V. W.; Emini, E. A. L-743,726 (DMP-266): a Novel Highly Potent Nonnucleoside Inhibitor of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Antimicrob. Agents Chemother. 1995, 39, 2602-2605.
5. Esnouf, R.; Ren, J.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. Mechanism of inhibition of reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol. 1995, 2, 303-308.
6. Montaner, J. S. G.; Reiss, P.; Cooper, D.; Vella, S.; Harris, M.; Conway, B.; Wainberg, M. A.; Smith, D.; Robinson, P.; Hall, D.; Myers, M.; Lange, J. M. A. for the INCAS Study Group. A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected Patients The INCAS Trial. JAMA 1998, 279, 930-937.
7. Staszewski, S.; Morales-Ramirez, J.; Tashima, K. T.; Rachlis, A.; Skiest, D.; Stanford, J.; Stryker, R.; Johnson, P.; Labriola, D. F.; Farina, D.; Manion, D. J.; Ruiz, N. M. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N. Engl. J. Med. 1999, 341, 1865-1873.
8. Wyatt, P. G.; Bethell, R. C.; Cammack, N.; Charon, D.; Dodie, N.; Dumaitre, B.; Evans, D. N.; Green, D. V. S.; Hopewell, P. L.; Humber, D. C.; Lamont, R. B.; Orr, D. C.; Plested, S. J.; Ryan, D. M.; Sollis, S. L.; Storer, R.; Weingarten, G. G. Benzophenone Derivatives: A Novel Series of Potent and Selective Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase. J. Med. Chem. 1995, 38, 1657-1665.
9. Stammers, D. K.; et al. Details of the crystallographic work will be published in due course.
10. Just, C. In Adv. Org. Chem: Methods and Results; Bohme, H., Viehe, H., Eds.; Wiley-Interscience: New York, 1976, 9, 225.
11. Ettel, V.; Hebky, J. The Preparation of Substances of the o-Aminoazotoluene Type and Their Derivatives Substituted in the Amino Group (I). Collect. Czech. Chem. Commun. 1948, 13, 161-176.
12. For experimental details, see: Chan, J. H.; Hong, J. S.; Hunter, R. N., III; Orr, G. F.; Cowan, J. R.; Sherman, D. B.; Sparks, S. M.; Reitter, B. E.; Andrews, C. W., III; Hazen, R. J.; St Clair, M.; Boone, L. R.; Ferris, R. G.; Creech, K. L.; Roberts, G. B.; Short, S. A.; Weaver, K. W.; Ott, R. J.; Ren, J. ; Hopkins, A.; Stuart, D. I.; Stammers, D. K. 2-Amino-6-arylsulfonylbenzonitriles as Non-nucleoside Reverse Transcriptase Inhibitors of HIV-1. J. Med. Chem. 2001, 44, 1866-1882.
13. See also: Chan, J.; Ferris, R.; Roberts, G.; Short, S.; Weaver, K.; Hazen, R.; Creech, K.; St Clair, M.; Dornsife, R.; Freeman, G.; Tidwell, J.; Romines, K.; Schaller, L.; Cowan, J.; Boone, L. In vitro Characterization of Novel Benzophenone Non-Nonucleoside Reverse Transcriptase Inhibitors. Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA., Feb 10-14, 2003, oral presentation no. 6.
14. Kellam, P.; Larde, r B. Recombinant Virus Assay: A Rapid, Phenotypic Assay for Assessment of Drug Susceptibility of Human Immunodeficiency Virus Type 1 Isolates. Antimicrob. Agents Chemother. 1994, 38, 23-30.
15. Miller, V.; V.; de Bethune, M. P.; Kober, A.; Sturmer, M.; Hertogs, K.; Pauwels, R.; Stoffels, P.; Staszewski, S. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the non-nucleoside reverse transcriptase inhibitor loviride. Antimicrob. Agents Chemother. 1998, 42, 3123-3129.
16. Havlir, D. V.; Eastman, S.; Gamst, A.; Richman, D. D. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J. Virol. 1996, 70, 7894-7899.
17. Maga, G.; Amacker, M.; Ruel, N.; Hubscher, U.; Spadari, S. Resistance to Nevirapine of HIV-1 Reverse Transcriptase Mutants: Loss of Stabilizing Interactions and Thermodynamic or Steric Barriers are Induced by Different Single Amino Acid Substitutions. J. Mol. Biol. 1997, 274, 738-747.
18. Demeter, L. M.; Shafer, R. W.; Meehan, P. M.; Holden-Wiltse, J.; Fischl, M. A.; Freimuth, W. W.; Para, M. F.; Reichman, R. C. Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260). Antimicrob. Agents Chemother. 2000, 44, 794-797.
19. Schinazi, R. F.; Larder, B. A.; Mellors, J. W. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int. Antiviral News 2000, 8, 65-91.